Actinium Pharmaceuticals presented data showing Actimab-A, combined with standard AML therapies, enhances killing of acute myeloid leukemia (AML) cells regardless of mutation type. The drug not only increases cytotoxicity but also reprograms AML cells to shift from proliferation to differentiation and apoptosis, potentially leading to deeper and longer-lasting remission. This mutation-agnostic effect supports Actimab-A as a universal backbone therapy for AML, complementing existing treatments with a manageable safety profile. These findings were highlighted at the AACR Annual Meeting, underscoring Actimab-A's promising role in improving AML patient outcomes.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
